Literature DB >> 23242818

Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.

Toru Aoyama1, Takaki Yoshikawa, Junya Shirai, Tsutomu Hayashi, Takanobu Yamada, Kazuhito Tsuchida, Shinichi Hasegawa, Haruhiko Cho, Norio Yukawa, Takashi Oshima, Yasushi Rino, Munetaka Masuda, Akira Tsuburaya.   

Abstract

BACKGROUND: Compliance of S-1 adjuvant chemotherapy is not high. The aim of the present study is to clarify risk factors for continuation of S-1 after gastrectomy.
METHODS: This retrospective study selected patients who underwent curative D2 surgery for gastric cancer, were diagnosed with stage 2/3 disease, creatinine clearance more than 60 ml/min, and received adjuvant S-1 at our institution between June of 2002 and December of 2011. Time to S-1 treatment failure (TTF) was calculated.
RESULTS: A total of 103 patients were selected for the present study. When TTF curve stratified by each clinical factor was compared by the log-rank test, body weight loss (BWL) of 15 % was regarded as a critical point. Both univariate and multivariate Cox proportional hazard analyses demonstrated that BWL was the significant independent risk factor. Moreover, BWL remained a significant factor in both the univariate and multivariate analyses in the subset excluding 8 patients who discontinued S-1 because of recurrence. The 6-month continuation rate was 66.4 % in the patients with BWL < 15 and 36.4 % in patients with BWL ≥ 15 % (P = .017).
CONCLUSIONS: BWL was the most important risk factor for the compliance of adjuvant chemotherapy with S-1 in the patients with stage 2/3 gastric cancer who underwent D2 gastrectomy. To improve drug compliance that leads to survival, it is a key to maintain body weight before starting S-1 adjuvant. Our study emphasizes the requirement for adequate studies of perioperative nutritional intervention in patients who receive gastrectomy for advanced gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242818     DOI: 10.1245/s10434-012-2776-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  43 in total

1.  Impact of being underweight on the long-term outcomes of patients with gastric cancer.

Authors:  Kazuhiro Migita; Tomoyoshi Takayama; Sohei Matsumoto; Kohei Wakatsuki; Tetsuya Tanaka; Masahiro Ito; Tomohiro Kunishige; Hiroshi Nakade; Yoshiyuki Nakajima
Journal:  Gastric Cancer       Date:  2015-08-23       Impact factor: 7.370

2.  Protocol for enhanced recovery after surgery improves short-term outcomes for patients with gastric cancer: a randomized clinical trial.

Authors:  Ryo Tanaka; Sang-Woong Lee; Masaru Kawai; Keitaro Tashiro; Satoshi Kawashima; Syuji Kagota; Kotaro Honda; Kazuhisa Uchiyama
Journal:  Gastric Cancer       Date:  2017-01-06       Impact factor: 7.370

3.  Multi-institutional prospective feasibility study to explore tolerability and efficacy of oral nutritional supplements for patients with gastric cancer undergoing gastrectomy (CCOG1301).

Authors:  Daisuke Kobayashi; Kiyoshi Ishigure; Yoshinari Mochizuki; Hiroshi Nakayama; Mitsuru Sakai; Seiji Ito; Hiroshi Kojima; Masaki Kajikawa; Masahiko Ando; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2016-11-24       Impact factor: 7.370

4.  Loss of skeletal muscle mass after curative gastrectomy is a poor prognostic factor.

Authors:  Naruji Kugimiya; Eijiro Harada; Kazuhito Oka; Daichi Kawamura; Yuki Suehiro; Yoshihiro Takemoto; Kimikazu Hamano
Journal:  Oncol Lett       Date:  2018-05-18       Impact factor: 2.967

5.  Should pylorus-preserving gastrectomy be performed for overweight/obese patients with gastric cancer?

Authors:  Masahiro Tsujiura; Naoki Hiki; Manabu Ohashi; Souya Nunobe; Koshi Kumagai; Satoshi Ida; Takuma Ohashi; Takeshi Sano; Toshiharu Yamaguchi
Journal:  Gastric Cancer       Date:  2019-03-19       Impact factor: 7.370

6.  More than 6 months of postoperative adjuvant chemotherapy results in loss of skeletal muscle: a challenge to the current standard of care.

Authors:  Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2015-04       Impact factor: 7.370

7.  Proposal of a Scoring Scale to Estimate Risk of the Discontinuation of S-1 Adjuvant Monotherapy in Patients with Stage II to III Gastric Cancer: A Multi-Institutional Dataset Analysis.

Authors:  Akimitsu Iizuka; Mitsuro Kanda; Seiji Ito; Yoshinari Mochizuki; Hitoshi Teramoto; Kiyoshi Ishigure; Toshifumi Murai; Takahiro Asada; Akiharu Ishiyama; Hidenobu Matsushita; Chie Tanaka; Daisuke Kobayashi; Michitaka Fujiwara; Kenta Murotani; Yasuhiro Kodera
Journal:  World J Surg       Date:  2019-08       Impact factor: 3.352

8.  Does a laparoscopic approach attenuate the body weight loss and lean body mass loss observed in open distal gastrectomy for gastric cancer? a single-institution exploratory analysis of the JCOG 0912 phase III trial.

Authors:  Toru Aoyama; Tsutomu Sato; Tsutomu Hayashi; Takanobu Yamada; Haruhiko Cho; Takashi Ogata; Koji Oba; Takaki Yoshikawa
Journal:  Gastric Cancer       Date:  2017-06-16       Impact factor: 7.370

9.  Clinical outcomes of gastric tube reconstruction following laparoscopic proximal gastrectomy for early gastric cancer in the upper third of the stomach: experience with 100 consecutive cases.

Authors:  Yoshitaka Toyomasu; Erito Mochiki; Toru Ishiguro; Tetsuya Ito; Okihide Suzuki; Kyoichi Ogata; Youichi Kumagai; Keiichiro Ishibashi; Hiroshi Saeki; Ken Shirabe; Hideyuki Ishida
Journal:  Langenbecks Arch Surg       Date:  2021-02-21       Impact factor: 3.445

10.  Patterns and Predictors of Weight Loss After Gastrectomy for Cancer.

Authors:  Jeremy L Davis; Luke V Selby; Joanne F Chou; Mark Schattner; David H Ilson; Marinela Capanu; Murray F Brennan; Daniel G Coit; Vivian E Strong
Journal:  Ann Surg Oncol       Date:  2016-01-05       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.